Literature DB >> 10392632

Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: a report from the Chromosomes and Morphology (CHAMP) study group.

R Sciot1, J Rosai, P Dal Cin, I de Wever, C D Fletcher, N Mandahl, F Mertens, F Mitelman, A Rydholm, G Tallini, H van den Berghe, R Vanni, H Willén.   

Abstract

The karyotypes of 44 specimens from 35 patients with localized (n = 19) or diffuse (n = 16) tenosynovial giant cell tumors were studied. The majority of cases in both categories (11 of 19 localized; 12 of 16 diffuse) displayed clonal chromosomal aberrations, with a complex karyotype in three cases and a simple chromosomal aberration in the others. No difference in the distribution of karyotypic abnormalities was found between the localized and diffuse form except for trisomies (usually of chromosomes 5 and/or 7), which were more frequent in the diffuse type. The short arm of chromosome 1 (1p11-13) was most frequently rearranged, with 7 of 11 localized and 7 of 12 diffuse lesions affected. These findings indicate that the localized and diffuse forms of tenosynovial giant cell tumor might represent two morphologic manifestations of the same entity. The high frequency of clonal chromosomal abnormalities, with a clustering of structural rearrangements to 1p11-13, suggests that this disease is most likely neoplastic in nature and paves the way to search for gene(s) that might be involved in its development.

Entities:  

Mesh:

Year:  1999        PMID: 10392632

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

1.  Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions.

Authors:  Brian P Rubin
Journal:  Skeletal Radiol       Date:  2007-04       Impact factor: 2.199

2.  Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  [Tenosynovial giant cell tumor].

Authors:  C Kuhnen; K-M Müller; S Rabstein; A Kasprzynski; P Herter
Journal:  Pathologe       Date:  2005-03       Impact factor: 1.011

4.  Diffuse-type giant cell tumor of the subcutaneous thigh.

Authors:  D A Sanghvi; N C Purandare; N A Jambhekar; M G Agarwal; A Agarwal
Journal:  Skeletal Radiol       Date:  2006-03-25       Impact factor: 2.199

5.  [Erosive intervertebral joint lesions. A case of pigmented villonodular synovitis].

Authors:  J Hermann; E Stadlmaier; Ch Aigner; E Spuller; P Reittner; W Graninger
Journal:  Z Rheumatol       Date:  2007-03       Impact factor: 1.372

6.  A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.

Authors:  Robert B West; Brian P Rubin; Melinda A Miller; Subbaya Subramanian; Gulsah Kaygusuz; Kelli Montgomery; Shirley Zhu; Robert J Marinelli; Alessandro De Luca; Erinn Downs-Kelly; John R Goldblum; Christopher L Corless; Patrick O Brown; C Blake Gilks; Torsten O Nielsen; David Huntsman; Matt van de Rijn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-06       Impact factor: 11.205

7.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

8.  CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 9.  Tenosynovial giant cell tumor arising from the posterior cruciate ligament: a case report and literature review.

Authors:  Zhihong Xu; Ping Mao; Dongyang Chen; Dongquan Shi; Jin Dai; Yao Yao; Qing Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

10.  Molecular cytogenetic characterization of tenosynovial giant cell tumors.

Authors:  Petter Brandal; Bodil Bjerkehagen; Sverre Heim
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.